Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA Scheduled To Vote Today on Savient’s Gout Drug

By Pharmaceutical Processing | June 16, 2009

WASHINGTON (AP) — A panel of arthritis experts is scheduled to vote Tuesday on whether a gout drug made by Savient Pharmaceuticals should be approved, despite a high number of heart-related side effects seen during testing. The FDA said in documents posted last week that the drug Krystexxa appears effective at treating pain and swelling associated with gout, a condition caused by a buildup of uric acid in the body. But the FDA has asked an outside panel of medical specialists to weigh in on negative side effects reported with the drug, including heart problems and allergic reactions. Overall, about 24 percent of patients taking Krystexxa suffered a serious side effect, compared with 12 percent of patients taking a placebo pill, the FDA said. There were six deaths among patients taking the drug compared with three among patients taking placebo, though the FDA noted many of them had pre-existing heart conditions. The FDA plans to ask its experts whether additional safety studies of the drug are needed. The agency is not required to follow the group’s advice, though it usually does. A final decision on Savient’s drug is expected by the end of July. Despite the safety concerns outlined last week, Wall Street analysts expect a positive outcome for the company on Tuesday. “The briefing document was milder than we expected, and seems to correspond to our hypothesis that the benefit to Krystexxa outweighs the risk,” Roth Capital Partners analyst Andrew Vaino wrote in a research note Friday. Savient Pharmaceuticals is based in East Brunswick, N.J., and specializes in niche drugs for under-treated diseases.

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE